NCT03671733Unknown3 期
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
Xiangya Hospital of Central South University1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2018年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Weight Change at 3 months
研究概览
简要总结
This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 to 65 years (to the date of screening)；
- •The newly diagnosed obese patients (BMI greater than 28 kg/m2) or abdominal obesity (male waist circumference is greater than 90cm, female waist is greater than 85cm).
- •Nearly a month have not used weight-related drugs,including various weight-loss drugs,GLP-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid drugs,etc;Or recently used weight-related drugs but the stable dose was more than 1 month,and the drug dose remained constant or decreased during the trial.
- •Weight stable for more than 3 months (weight fluctuations <5%).
排除标准
- •pregnant female.
- •Secondary diseases caused by other diseases: including hypothyroidism, increased cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of drug-induced obesity, and others.
- •Severe cardiovascular and cerebrovascular diseases (heart failure, myocardial infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or pulmonary insufficiency, renal failure, severe hepatitis.
- •Combined with acute complications of diabetes such as ketoacidosis, lactic acidosis, hyperosmolar state of diabetes.
- •Nearly a month had surgery, trauma, infection and so on.
- •Limb deformity incomplete, difficult to accurately determine the height, weight and other physical indicators.
- •Poor medication compliance or serious side effects (severe rash, syncope, etc.).
研究组 & 干预措施
Liraglutide
Experimental
Administered subcutaneously (s.c., under the skin) once daily for 12 weeks.
干预措施: Liraglutide (Drug)
Exenatide
Experimental
Administered subcutaneously (s.c., under the skin) twice daily for 12 weeks.
干预措施: Exenatide (Drug)
Exenatide Microspheres for Injection
Experimental
Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
干预措施: Exenatide Microspheres for Injection (Drug)
结局指标
主要结局
Weight Change at 3 months
时间窗: baseline , 3 months
Measured in kilograms
次要结局
- Change in systolic blood pressure(baseline and 3 months)
- Change in waist circumference(baseline and 3 months)
- Change in diastolic blood pressure(baseline and 3 months)
- Change in HbA1c(baseline and 3 months)
- Change in insulin(baseline and 3 months)
- Change in lipids-total cholesterol(baseline and 3 months)
- Change in lipids-low density lipoprotein cholesterol(baseline and 3 months)
- Change in lipids-high density lipoprotein cholesterol(baseline and 3 months)
- Change in Uric Acid(baseline and 3 months)
- Change in tumor necrosis factor(baseline and 3 months)
- Change in plasma glucose(baseline and 3 months)
- Change in lipids-triglycerides(baseline and 3 months)
- Change in lipids-free fatty acids(baseline and 3 months)
- Change in interleukin-6(baseline and 3 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes MellitusMetforminObesity, AbdominalAbdominal FatNon-Alcoholic Fatty Liver DiseaseMetabolism Disorder, GlucoseMetabolism Disorder, LipidDiabetes Mellitus, Type 2NCT05779644RenJi Hospital300
已完成
不适用
The Interaction Between Appetite HormonesObesityNCT02094183University of Copenhagen58
Unknown
2 期
Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?Impaired Glucose Tolerance Associated With DrugsNCT01845259Psychiatric Centre Rigshospitalet103
招募中
4 期
Impact GLP-1 Agonists Following BariatricMorbid ObesityMetabolic SyndromeObstructive Sleep Apnea of AdultDiabetes MellitusHypertensionNCT06132477University of Missouri-Columbia150
招募中
不适用
Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric SurgeryObesityNCT06278285Centre Hospitalier Universitaire de Nice40